HER-2 antagonists (Cengent)

N/A

Report date: 2025/02/01 20:00:06

NME

Base Information

Drug NameHER-2 antagonists (Cengent)

Drug Alias NameHER-2 antagonists (SBI)Her 2 inhibitors (Structural Bioinformatics)Her 2 inhibitors/EGF antagonists (Structural Bioinformatics)Her 2 inhibitors/EGF antagonists (Cengent)Her 2 inhibitors (Cengent)

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonistsEpidermal growth factor receptor erbB1 antagonists

TargetsReceptor protein-tyrosine kinase erbB-2Epidermal growth factor receptor erbB1

Therapy Area/IndicationsBreast NeoplasmsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusDiscontinued (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesCengent Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesCengent Therapeutics Inc

Active IndicationsN/A

Inactive IndicationsBreast NeoplasmsNeoplasms

Other Information

ATC CodeN/A